This article is part of Pulmonology Advisor‘s coverage of the American Thoracic Society International Conference, taking place in Dallas, Texas. Our staff will report on medical research related to asthma and other respiratory conditions, conducted by experts in the field. Check back regularly for more news from ATS 2019.


DALLAS — Patients with corticosteroid-dependent severe asthma who received dupilumab had better asthma control and health-related quality of life compared with those who received placebo, according to the results of the phase 3 LIBERTY ASTHMA VENTURE study (ClinicalTrials.gov Identifier: NCT02528214), presented at the American Thoracic Society International Conference, held May 17-22, in Dallas, Texas.

Asthma control, as assessed by the 5-item Asthma Control Questionnaire (ACQ-5), and health-related quality of life, as assessed by the self-administered 7-item Asthma Quality of Life Questionnaire (AQLQ), were compared among patients with corticosteroid-dependent severe asthma while they received either dupilumab or placebo for 24 weeks. All patients were ≥12 years of age and had moderate to severe eosinophilic or corticosteroid-dependent asthma. Dupilumab is an anti-interleukin (IL)-4 receptor α monoclonal antibody that inhibits signaling of IL-4 and IL-13.

Of the 210 participants in the study, 103 were in the dupilumab group and 107 were in the placebo group. The mean baseline ACQ-5 scores were 2.42 and 2.58, and the mean baseline AQLQ scores were 4.38 and 4.31 in the dupilumab and placebo groups, respectively. In the dupilumab group, asthma control rapidly improved and remained stable through week 24. Eosinophilia was the most frequent adverse event, occurring in 14% of the dupilumab group vs 1% of the placebo group.

Related Articles

Visit Pulmonology Advisor‘s conference section for continuous coverage from ATS 2019.


Reference

Ford LB, Rabe KF, Wolfe RN, et al. Dupilumab improved asthma control and health-related quality of life in patients with oral-corticosteroid-dependent severe asthma in the phase 3 LIBERTY ASTHMA VENTURE study. Presented at: the American Thoracic Society International Conference; May 20, 2019; Dallas, TX. Abstract A2666/501.